Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
Phase 1/2 Completed
22 enrolled 13 charts
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Phase 1/2 Completed
127 enrolled 16 charts
BURN
Phase 1/2 Completed
350 enrolled
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Phase 1/2 Completed
77 enrolled
Radiation and Androgen Ablation for Prostate Cancer
Phase 1/2 Completed
45 enrolled 11 charts
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
Phase 1/2 Completed
40 enrolled
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Phase 1/2 Completed
272 enrolled
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
44 enrolled 22 charts
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Phase 1/2 Completed
16 enrolled
INSTIN
Phase 1/2 Completed
18 enrolled
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Phase 1/2 Completed
19 enrolled
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
Phase 1/2 Completed
43 enrolled 15 charts
Study of DF9001 in Patients With Advanced Solid Tumors
Phase 1/2 Completed
24 enrolled
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Phase 1/2 Completed
98 enrolled
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Phase 1/2 Completed
59 enrolled 20 charts
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
ROADSTER
Phase 1/2 Completed
3 enrolled
TACITO
Phase 1/2 Completed
50 enrolled
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Phase 1/2 Completed
45 enrolled 30 charts
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Phase 1/2 Completed
173 enrolled
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Phase 1/2 Completed
35 enrolled
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Phase 1/2 Completed
15 enrolled 16 charts
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Phase 1/2 Completed
84 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Phase 1/2 Completed
23 enrolled
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
Phase 1/2 Completed
20 enrolled
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Phase 1/2 Completed
31 enrolled 11 charts
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Phase 1/2 Completed
40 enrolled 11 charts
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Phase 1/2 Completed
9 enrolled 9 charts
MESODEC
Phase 1/2 Completed
28 enrolled
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Phase 1/2 Completed
83 enrolled 14 charts
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Phase 1/2 Completed
45 enrolled 17 charts
ICRA
Phase 1/2 Completed
53 enrolled
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Phase 1/2 Completed
46 enrolled 11 charts
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
44 enrolled
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
PICture
Phase 1/2 Completed
75 enrolled
MOVIE
Phase 1/2 Completed
126 enrolled
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy
Phase 1/2 Completed
21 enrolled
NICARAGUA
Phase 1/2 Completed
67 enrolled
UV1/hTERT2012P
Phase 1/2 Completed
22 enrolled
Dendritic Cell Vaccination for Patients with Solid Tumors
Phase 1/2 Completed
48 enrolled
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1/2 Completed
42 enrolled 14 charts
A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Phase 1/2 Completed
32 enrolled
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Phase 1/2 Completed
60 enrolled
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Phase 1/2 Completed
49 enrolled